Media Centre
Latest press releases
-
Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
-
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
-
Fixed-duration Calquence plus venetoclax demonstrated superior progression-free survival vs. standard of care in previously untreated chronic lymphocytic leukaemia, with 77% of patients progression free at three years in AMPLIFY Phase III trial
-
Imfinzi granted Priority Review in the US for patients with muscle-invasive bladder cancer
-
Imfinzi approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
